

Las Vegas, NV; September 22, 2022 – **FIRST IMPORTANT STEPS FOR NIKA BIOTECHNOLOGY, INC. IN ITS ENTRY TO THE PHARMACEUTICAL INDUSTRY**

In pursuit of the goal to create a sustainable business model in the pharmaceutical industry, Nika BioTechnology, Inc. (“NIKA”) united its efforts with Nika Pharmaceuticals, Inc. for the production, distribution, joint financing that is split in equal parts and a distribution of the profits, which are also split in equal part. As such, in essence NIKA owns 50% of the rights for the production of and distribution of 6 drugs in injection form, two of which – ITV-1 and TNG – have successfully undergone through clinical trials on patients suffering from AIDS in the *Specialized Hospital for Active Treatment of Infectious and Parasitic Deceases “Professor Ivan Kirov”*, situated in Sofia, Bulgaria. What is next is their entry to the market, for which purpose 3 validation batches for ITV-1 and TNG each will be produced.

NIKA also owns 50% of the rights for production and distribution of 8 patents and technologies for dietary supplements, which have proven their usefulness for the human and healing effect. The dietary supplements are named Physiolong, Carotilen, Fructin, Dry Boza, Antocilen C, Hypocholestin, Biodetoxin, Silymaron. (Find out more at [NIKA products](#)) The first batch of Physiolong and Carotilen have now been produced and are already on the market in Bulgaria. The next steps are to release in stages the two dietary supplements in Greece, Romania, Germany, Spain and gradually in a series of other countries in Europe, Asia, and Africa. Currently, the company does market research and is in talks to get national distributors to launch the supplements in the US market.

NIKA will soon attain 40% stake ownership in Nika Europe, Ltd. (“Nika Europe”) through which the company will have a firm foothold on the markets of Europe, Asia, and Africa. Nika Europe is preparing the construction of a pharmaceutical factory that is comprised of different manufacturing facilities for the production of drugs in injection, tablet and other forms. The factory will have enough production capacity to secure the needs of NIKA. Dimitar Savov and his team works hard on the conceptual project and its completion as a technical project should be ready by November 30, 2022. Currently, the company is selecting a constructed industrial building for purchase, which will give the opportunity for the first manufacturing facility for the drugs ITV-1 and TNG to be ready by July 30, 2023 at the latest.

The sale of the drugs is secured with agreements for exclusive rights for various countries, for which purpose the company has chosen and is selecting reliable partners who have the necessary qualities to develop the respective markets. The estimated net profit from one set of ITV-1 and TNG is \$1,600, which would presuppose a yearly profit for NIKA that drastically exceeds 100 million USD. The efficacy of ITV-1 and TNG has been proven in the aforementioned clinical trials, which can be seen in the attached [Final Report](#). The two drugs will significantly contribute to the fight against the horrible AIDS disease, which has been deemed as the plague of the 20th century.

Dimitar Savov, the President of NIKA, stated, “Dear investors, thank you for the support, as with your investment you are assisting us in developing NIKA into a company, which creates and provides to humanity drugs and dietary supplements that are based on natural biological

basis, which are not only beneficial to humans, but do not harbor side effects. We are assuring your that we, the management of NIKA, are working responsibly and tirelessly for the establishment of NIKA as a company with a professional sustainable business model that is designed for the protection of the investments of its investors. “

FORWARD LOOKING STATEMENT: Certain information set forth in this press release of Nika BioTechnology, Inc. contains “forward-looking information”. Except for statements of historical fact, the information contained herein constitutes forward-looking statements and includes, but is not limited to, (i) the expected development of the Company’s business, projects, and joint ventures; (ii) execution of the Company’s vision and growth strategy, including with respect to global growth; (iii) completion of the Company’s projects that are currently underway, in development or otherwise under consideration. Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment.

These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements.

Although forward-looking statements contained in this presentation are based upon what management of the Nika BioTechnology, Inc. believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.